Which has higher valuation & earnings, APYX or NSPR?

Apyx Medical has higher revenue and earnings than InspireMD. Apyx Medical is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apyx Medical $52.84M 2.06 -$11.21M -$0.20 N/A InspireMD $10.84M 2.23 -$19.92M -$0.64 N/A

Is APYX or NSPR more profitable?

Apyx Medical has a net margin of -14.78% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Apyx Medical's return on equity. Company Net Margins Return on Equity Return on Assets Apyx Medical -14.78% -76.60% -13.91% InspireMD -413.96% -69.42% -57.68%

Which has stronger earnings & valuation, ECOR or NSPR?

electroCore has higher revenue and earnings than InspireMD. electroCore is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio electroCore $32.03M 2.72 -$13.97M -$1.66 N/A InspireMD $10.84M 2.23 -$19.92M -$0.64 N/A

Is ECOR or NSPR more profitable?

electroCore has a net margin of -39.96% compared to InspireMD's net margin of -413.96%. electroCore's return on equity of 0.00% beat InspireMD's return on equity. Company Net Margins Return on Equity Return on Assets electroCore -39.96% N/A -81.35% InspireMD -413.96% -69.42% -57.68%

Do analysts recommend NSPR or KEQU?

InspireMD currently has a consensus target price of $4.50, suggesting a potential upside of 763.72%. Given InspireMD's stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Kewaunee Scientific. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InspireMD 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Kewaunee Scientific 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NSPR or NRXS more profitable?

InspireMD has a net margin of -413.96% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat InspireMD's return on equity. Company Net Margins Return on Equity Return on Assets InspireMD -413.96% -69.42% -57.68% NeurAxis -492.76% N/A -641.25%

InspireMD (NSPR) Competitors

$0.52 +0.04 (+8.54%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.54 +0.02 (+3.26%)

As of 10/9/2026 07:47 PM Eastern

Compare

NSPR vs. CNXU, APYX, ECOR, KEQU, and NRXS

Should you buy InspireMD stock or one of its competitors? InspireMD's main competitors and comparable companies include Conexeu Sciences (CNXU), Apyx Medical (APYX), electroCore (ECOR), Kewaunee Scientific (KEQU), and NeurAxis (NRXS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does InspireMD compare to Conexeu Sciences?

Conexeu Sciences (NASDAQ:CNXU) and InspireMD (NYSE:NSPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Conexeu Sciences currently has a consensus price target of $20.00, suggesting a potential upside of 414.14%. InspireMD has a consensus price target of $4.50, suggesting a potential upside of 763.72%. Given InspireMD's stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than Conexeu Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conexeu Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Conexeu Sciences had 5 more articles in the media than InspireMD. MarketBeat recorded 5 mentions for Conexeu Sciences and 0 mentions for InspireMD. Conexeu Sciences' average media sentiment score of 0.15 beat InspireMD's score of 0.00 indicating that Conexeu Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Conexeu Sciences	Neutral
InspireMD	Neutral

44.8% of InspireMD shares are held by institutional investors. 25.0% of InspireMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Conexeu Sciences has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Conexeu Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Conexeu Sciences	N/A	-200.20%	-177.26%
InspireMD	-413.96%	-69.42%	-57.68%

Conexeu Sciences has higher earnings, but lower revenue than InspireMD. Conexeu Sciences is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Conexeu Sciences	N/A	N/A	-$3.92M	-$0.40	N/A
InspireMD	$10.84M	2.23	-$19.92M	-$0.64	N/A

Summary

InspireMD beats Conexeu Sciences on 9 of the 14 factors compared between the two stocks.

How does InspireMD compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and InspireMD (NYSE:NSPR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

In the previous week, Apyx Medical had 1 more articles in the media than InspireMD. MarketBeat recorded 1 mentions for Apyx Medical and 0 mentions for InspireMD. Apyx Medical's average media sentiment score of 0.00 equaled InspireMD'saverage media sentiment score.

Company	Overall Sentiment
Apyx Medical	Neutral
InspireMD	Neutral

55.3% of Apyx Medical shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 15.9% of Apyx Medical shares are held by insiders. Comparatively, 25.0% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Apyx Medical has a net margin of -14.78% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Apyx Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-14.78%	-76.60%	-13.91%
InspireMD	-413.96%	-69.42%	-57.68%

Apyx Medical presently has a consensus target price of $6.50, suggesting a potential upside of 150.97%. InspireMD has a consensus target price of $4.50, suggesting a potential upside of 763.72%. Given InspireMD's stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than Apyx Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Apyx Medical has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, InspireMD has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Apyx Medical has higher revenue and earnings than InspireMD. Apyx Medical is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$52.84M	2.06	-$11.21M	-$0.20	N/A
InspireMD	$10.84M	2.23	-$19.92M	-$0.64	N/A

Summary

Apyx Medical beats InspireMD on 10 of the 16 factors compared between the two stocks.

How does InspireMD compare to electroCore?

electroCore (NASDAQ:ECOR) and InspireMD (NYSE:NSPR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

26.7% of electroCore shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 7.8% of electroCore shares are owned by insiders. Comparatively, 25.0% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

electroCore has a net margin of -39.96% compared to InspireMD's net margin of -413.96%. electroCore's return on equity of 0.00% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-39.96%	N/A	-81.35%
InspireMD	-413.96%	-69.42%	-57.68%

electroCore has higher revenue and earnings than InspireMD. electroCore is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03M	2.72	-$13.97M	-$1.66	N/A
InspireMD	$10.84M	2.23	-$19.92M	-$0.64	N/A

electroCore has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, InspireMD has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

In the previous week, electroCore had 2 more articles in the media than InspireMD. MarketBeat recorded 2 mentions for electroCore and 0 mentions for InspireMD. electroCore's average media sentiment score of 0.00 equaled InspireMD'saverage media sentiment score.

Company	Overall Sentiment
electroCore	Neutral
InspireMD	Neutral

electroCore presently has a consensus price target of $18.00, suggesting a potential upside of 86.34%. InspireMD has a consensus price target of $4.50, suggesting a potential upside of 763.72%. Given InspireMD's stronger consensus rating and higher probable upside, analysts clearly believe InspireMD is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

InspireMD beats electroCore on 8 of the 15 factors compared between the two stocks.

How does InspireMD compare to Kewaunee Scientific?

InspireMD (NYSE:NSPR) and Kewaunee Scientific (NASDAQ:KEQU) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

InspireMD has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Kewaunee Scientific has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

InspireMD currently has a consensus target price of $4.50, suggesting a potential upside of 763.72%. Given InspireMD's stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Kewaunee Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Kewaunee Scientific	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 32.7% of Kewaunee Scientific shares are owned by institutional investors. 25.0% of InspireMD shares are owned by company insiders. Comparatively, 14.1% of Kewaunee Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Kewaunee Scientific had 2 more articles in the media than InspireMD. MarketBeat recorded 2 mentions for Kewaunee Scientific and 0 mentions for InspireMD. Kewaunee Scientific's average media sentiment score of 0.75 beat InspireMD's score of 0.00 indicating that Kewaunee Scientific is being referred to more favorably in the news media.

Company	Overall Sentiment
InspireMD	Neutral
Kewaunee Scientific	Positive

Kewaunee Scientific has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$10.84M	2.23	-$19.92M	-$0.64	N/A
Kewaunee Scientific	$282M	0.35	$9.62M	$2.76	12.24

Kewaunee Scientific has a net margin of 2.97% compared to InspireMD's net margin of -413.96%. Kewaunee Scientific's return on equity of 11.61% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
Kewaunee Scientific	2.97%	11.61%	4.82%

Summary

Kewaunee Scientific beats InspireMD on 9 of the 16 factors compared between the two stocks.

How does InspireMD compare to NeurAxis?

InspireMD (NYSE:NSPR) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

InspireMD has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, NeurAxis has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

In the previous week, NeurAxis had 9 more articles in the media than InspireMD. MarketBeat recorded 9 mentions for NeurAxis and 0 mentions for InspireMD. NeurAxis' average media sentiment score of 0.86 beat InspireMD's score of 0.00 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Overall Sentiment
InspireMD	Neutral
NeurAxis	Positive

NeurAxis has lower revenue, but higher earnings than InspireMD. NeurAxis is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$10.84M	2.23	-$19.92M	-$0.64	N/A
NeurAxis	$5.32M	16.37	-$14.63M	-$0.78	N/A

InspireMD presently has a consensus target price of $4.50, suggesting a potential upside of 763.72%. NeurAxis has a consensus target price of $13.00, suggesting a potential upside of 87.59%. Given InspireMD's stronger consensus rating and higher possible upside, equities analysts clearly believe InspireMD is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
NeurAxis	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

InspireMD has a net margin of -413.96% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
NeurAxis	-492.76%	N/A	-641.25%

44.8% of InspireMD shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 25.0% of InspireMD shares are owned by insiders. Comparatively, 21.1% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

InspireMD beats NeurAxis on 10 of the 16 factors compared between the two stocks.

Get InspireMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NSPR vs. The Competition

Export

Metric	InspireMD	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$22.32M	$5.44B	$7.16B	$22.94B
Dividend Yield	N/A	1.78%	2.53%	3.72%
P/E Ratio	-0.69	25.57	274.15	28.60
Price / Sales	2.23	83.25	635.98	14.87
Price / Cash	N/A	31.87	76.38	37.72
Price / Book	0.28	5.93	11.21	4.72
Net Income	-$19.92M	$146.18M	$3.50B	$1.07B
7 Day Performance	-16.31%	-0.38%	-0.90%	0.35%
1 Month Performance	-32.25%	-2.02%	-4.44%	-2.93%
1 Year Performance	-77.83%	5.08%	6.96%	9.26%

InspireMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NSPR InspireMD	N/A	$0.52 +8.5%	$4.50 +763.7%	-78.3%	$22.32M	$10.84M	N/A	127	Gap Up High Trading Volume
CNXU Conexeu Sciences	2.0999 of 5 stars	$3.71 -1.6%	$20.00 +439.1%	N/A	$106.34M	N/A	N/A	4
APYX Apyx Medical	2.8243 of 5 stars	$2.60 +4.0%	$6.50 +150.0%	-13.4%	$105.31M	$52.84M	N/A	205	High Trading Volume
ECOR electroCore	2.6264 of 5 stars	$10.88 -1.4%	$18.00 +65.4%	+83.7%	$99.45M	$36.97M	N/A	83	Positive News
KEQU Kewaunee Scientific	1.6166 of 5 stars	$34.32 +0.9%	N/A	-21.7%	$98.50M	$282M	12.43	1,231

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NSPR) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InspireMD (NSPR) Competitors

NSPR vs. CNXU, APYX, ECOR, KEQU, and NRXS

How does InspireMD compare to Conexeu Sciences?

Summary

How does InspireMD compare to Apyx Medical?

Summary

How does InspireMD compare to electroCore?

Summary

How does InspireMD compare to Kewaunee Scientific?

Summary

How does InspireMD compare to NeurAxis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NSPR vs. The Competition

InspireMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InspireMD (NSPR) Competitors

NSPR vs. CNXU, APYX, ECOR, KEQU, and NRXS

How does InspireMD compare to Conexeu Sciences?

Do analysts prefer CNXU or NSPR?

Does the media favor CNXU or NSPR?

Do insiders and institutionals have more ownership in CNXU or NSPR?

Is CNXU or NSPR more profitable?

Which has better earnings & valuation, CNXU or NSPR?

Summary

How does InspireMD compare to Apyx Medical?

Does the media favor APYX or NSPR?

Do insiders & institutionals have more ownership in APYX or NSPR?

Is APYX or NSPR more profitable?

Do analysts prefer APYX or NSPR?

Which has more volatility & risk, APYX or NSPR?

Which has higher valuation & earnings, APYX or NSPR?

Summary

How does InspireMD compare to electroCore?

Do institutionals and insiders hold more shares of ECOR or NSPR?

Is ECOR or NSPR more profitable?

Which has stronger earnings & valuation, ECOR or NSPR?

Which has more volatility & risk, ECOR or NSPR?

Does the media refer more to ECOR or NSPR?

Do analysts recommend ECOR or NSPR?

Summary

How does InspireMD compare to Kewaunee Scientific?

Which has more risk and volatility, NSPR or KEQU?

Do analysts recommend NSPR or KEQU?

Do institutionals & insiders hold more shares of NSPR or KEQU?

Does the media refer more to NSPR or KEQU?

Which has better earnings and valuation, NSPR or KEQU?

Is NSPR or KEQU more profitable?

Summary

How does InspireMD compare to NeurAxis?

Which has more volatility and risk, NSPR or NRXS?

Does the media prefer NSPR or NRXS?

Which has higher valuation and earnings, NSPR or NRXS?

Do analysts recommend NSPR or NRXS?

Is NSPR or NRXS more profitable?

Do institutionals and insiders hold more shares of NSPR or NRXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NSPR vs. The Competition

InspireMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools